Effectiveness of Surfacen® Use in Neonatal Respiratory Distress

Abstract

Neonatal respiratory distress syndrome is a serious disease that affects infant mortality. Its cause, due to a surfactant deficiency, has been studied to develop medications aimed at preventing newborn deaths. The objective of this study is to demonstrate the effectiveness of Surfacen^® use in neonatal respiratory distress. A literature review was conducted between June and July 2025 in Spanish, using keywords from the Health Sciences Descriptors. Information from the last five years was collected through Google Scholar and the SciELO, LILACS, and PubMed databases. Only 20 studies met the inclusion criteria. Analysis and synthesis methods were used, allowing for the interpretation of the literature found and the organization of knowledge. The use of surfactant in patients with neonatal respiratory distress improves oxygenation and reduces the need for mechanical ventilation. The decrease in hospital stay and infant mortality, along with significant improvements in parameters such as the exhaled flow rate, validate its efficacy and safety. Surfacen^® is a highly effective drug for treating respiratory diseases such as neonatal respiratory distress. Its ability to reduce surface tension and facilitate alveolar expansion demonstrates its effectiveness in improving oxygenation and minimizing the use of mechanical ventilation.